The Rise of the "Medical Ghost": AI, Automation and the Future of Healthcare's invisible workforce
- Nelson Advisors
- 2 minutes ago
- 17 min read
Executive Summary: The Automation Imperative and the Rise of the Medical Ghost
Thesis Statement: The Convergence of Pervasive Computing and Closed-Loop Medical Systems
The emergence of deeply integrated, autonomous health technologies, termed the "Medical Ghost" in this analysis, signals a paradigm shift in healthcare delivery. This new class of medical devices and software operates entirely in the background, utilising ambient sensors to diagnose conditions and autonomously execute therapeutic interventions without requiring conscious user awareness or interaction. This convergence of pervasive computing and closed-loop medical systems necessitates an immediate and comprehensive overhaul of prevailing regulatory consent models, data privacy frameworks and liability assignment principles. The inherent nature of the Medical Ghost challenges the foundational principle of patient autonomy by introducing highly effective, non-conscious therapeutic interventions optimized for clinical efficacy.
Key Findings Snapshot
Analysis confirms that the technical foundation for the Medical Ghost is clinically validated and nearing market readiness, driven by advancements in ambient sensing and environmental neuro-modulation.
However, the operationalisation of these systems introduces existential ethical risks centered around informed consent and the rise of algorithmic paternalism. Legally, significant gaps exist at the intersection of consumer Internet of Things (IoT) infrastructure and regulated high-risk healthcare, demanding a unified accountability architecture that addresses inherent algorithmic biases and the erosion of mental privacy.
This report identifies that the pursuit of optimised health outcomes through automation directly confronts the traditional model of patient empowerment, requiring policy mandates for novel consent protocols and continuous equity auditing.
The Anatomy of Autonomy: Technical Feasibility and Clinical Validation
The foundational premise of the Medical Ghost, that highly subtle, environmental monitoring and intervention can occur autonomously, is supported by existing research validating both the pervasive sensing technology and the biological efficacy of non-invasive environmental modulation.
Defining the Closed-Loop Ambient Medical System (C-LAMS)
Pervasive Sensing as the Diagnostic Layer
The operational feasibility of the Medical Ghost relies fundamentally on unobtrusive, contactless monitoring technologies often grouped under ambient sensor systems. These systems utilise a range of devices integrated seamlessly into residential infrastructure, including passive infrared sensors, radiofrequency identification, magnetic switches and sensors for environmental factors such as temperature and light.
Unlike traditional wearable devices, these systems are designed to gather data on a continuous and pervasive basis, allowing senior citizens and patients with chronic conditions to maintain independence and privacy while ensuring continuous surveillance for indicators of physical or mental decline. The captured data, such as movement within a room or door movement, serves as a proxy for physical activity, gait speed, and sleep quality.
Digital Biomarker Extraction
The raw data collected by pervasive sensors is processed by advanced artificial intelligence (AI) to extract crucial digital biomarkers in real-time. These devices transmit data to the cloud via local Wi-Fi and mobile networks to derive metrics such as heart rate, respiration rate, heart rate variability, movements in bed, sleep duration, and sleep onset delay. Such ambient sensing systems (ASS) have demonstrated reliability in accurately measuring vital signs, and the resultant digital biomarkers are increasingly accepted as validated indicators for various health conditions and diseases. Furthermore, the integration of environmental and behavioral factors, such as time spent at home, suggests a route for monitoring conditions like anxiety disorder, complementing physiological metrics such as heart rate and sleep duration.
Closed-Loop Intervention
The crucial transition from passive monitoring to active therapeutic intervention defines the Medical Ghost. Traditional healthcare models often rely on physician review of patient data, followed by a prescription or clinical adjustment. The C-LAMS model, however, is inherently designed for autonomous, closed-loop operation. This mirrors a broader trend in personalised medicine that seeks to combine dose-optimised drug therapy with digital care solutions to improve outcomes and manage conditions that strain traditional delivery models.
Widespread use of such closed-loop systems is projected to yield significant reductions in long-term complications and associated healthcare spending, potentially generating substantial financial savings over time, despite high initial investment. The system functions as a predictive maintenance model for the human body, autonomously initiating actions based on algorithmic detection of suboptimal physiological states.
Validation of Non-Conscious Therapeutic Intervention
The conceptual framework of the Medical Ghost is grounded in clinical evidence demonstrating that subtle environmental changes can directly modulate neurological and physiological health, even without conscious patient input.
Environmental Neuro-Modulation
The outlier concept proposed, adjusting light or sound frequencies to mitigate neurological symptoms, is scientifically grounded. Long-term studies have shown that daily, noninvasive 40Hz light and sound stimulation can synchronise brain activity to a gamma rhythm. This intervention has been observed to help slow cognitive decline in individuals with late-onset Alzheimer’s disease, sustaining stronger cognitive performance and showing reduced levels of the tau protein biomarker over two years of treatment. The fact that such a noninvasive therapy, feasible for daily home use, can impact major disease biomarkers validates the premise that the environment can serve as a conduit for autonomous medical intervention.
Efficacy in Chronic and Age-Related Conditions
The application of environmental modulation extends beyond neurodegenerative diseases. Research demonstrates that the aging process and healthspan can be modified by an organism's ability to perceive and respond to changes in its environment, often involving pathways that promote survival during stress. Targeted interventions that incorporate environmental enrichment and physical activity are known to enhance neuroplasticity, which is crucial for preserving cognitive function in aging and neurodegenerative conditions. Specifically, research on animal models confirms that physical activity, such as voluntary running, can positively affect learning and short-term memory even in very old brains.For mobility and fall risk, remote monitoring devices utilising ambient technology are already recognised as beneficial, particularly for individuals with cognitive impairment, allowing them to live independently for longer.
Strategic Implications for Classification and Definition
The convergence of passive physiological monitoring and active environmental modulation creates unique regulatory and clinical complexities.
The system's technical readiness confirms that the immediate future of automated medicine involves the integration of diagnosis (via digital biomarkers derived from passive sensing ) and active treatment (via 40Hz modulation or environmental enrichment). This integration dictates that the system must be classified as a high-risk Software as a Medical Device (SaMD). While the FDA provides resources to identify authorised AI-enabled devices, the closed-loop, autonomous nature of the Ghost means it transcends simple diagnostic tools. It actively mitigates symptoms, potentially stabilizing gait or reducing neurodegenerative biomarkers. Consequently, this functionality likely places the device into a higher risk category, necessitating either the rigorous 510(k) pathway or, due to the novelty of the autonomous intervention mechanism, a De Novo authorisation. Regulatory oversight must shift from verifying a one-time product approval to a continuous authorisation model capable of validating adaptive algorithms that learn and adjust interventions autonomously over time without constant human oversight.
Furthermore, when subtle environmental adjustments, such as modifying light spectra or introducing specific sound frequencies, achieve clinically measurable outcomes—like mitigating tau protein pathology or stabilising gait they must be legally defined as medical "interventions" or "treatments." This classification is mandatory, even if the treatment is non-pharmacological, non-surgical, and delivered passively through residential infrastructure. This broadens the scope of medical malpractice and regulatory authority far beyond traditional clinical devices and into the consumer technology sector, requiring new levels of accountability from manufacturers whose products, by their autonomous therapeutic intent, are now medical systems.
Ethical Framework for Non-Conscious Medical Intervention
The Crisis of Autonomy: Consent, Paternalism and Non-Aware Interventions
The greatest strategic challenge posed by the Medical Ghost is the fundamental conflict between optimising health outcomes through automation and preserving the patient's right to conscious self-determination, a tension that shifts the healthcare paradigm from empowerment to automation.
The Erosion of Foundational Consent Principles
Autonomy vs. Best Interest
The legal and ethical history of medical practice mandates informed consent, a process requiring healthcare professionals to educate patients on the risks, benefits, and alternatives of any procedure or intervention.This principle, established legally by cases such as Schloendorff v. Society of New York Hospital in 1914, affirms that every competent adult has the right to determine what is done with their own body.
The Medical Ghost directly undermines this foundation by autonomously initiating interventions based solely on algorithmic evaluation. The system prioritises the patient's determined best interest, such as preemptive mitigation of neurological decline, over the patient’s immediate conscious autonomy to accept or reject the intervention.
The Exception of Presumed Consent
Currently, interventions without explicit, conscious consent are primarily justified in emergency trauma situations where the patient's capacity is temporarily altered or they are unable to decide, necessitating that the physician act in the patient’s presumed best interest. The Medical Ghost attempts to apply a form of presumed or deferred consent to a patient who is technically a competent adult, in a non-emergency, chronic setting. The justification rests on the continuous, automated judgment of the AI system operating "in the background." This application radically expands the scope of presumed consent, demanding clarification on whether the desire for optimal, continuous health outcomes can override a competent adult’s basic right to awareness of medical action.
Patient Engagement vs. Algorithmic Optimisation
The debate surrounding automated health management hinges on the value of patient participation.
The Deskilling of the Patient
The automation of disease management, while technically promising, risks inducing 'deskilling', the loss of the patient’s basic ability to manage or understand their chronic condition.Critics of full automation argue that removing the patient from reviewing their own data or manually engaging with their care regimen sacrifices a key opportunity for empowerment and education.The empowered patient has been central to modern healthcare models, leading to new physician roles as mentors or guides. Full automation risks reversing this trajectory.
The Necessity of Automation
Conversely, relying on manual data entry is often impractical and inefficient. For chronic conditions involving fluctuating cognitive capacity, such as dementia or Parkinson’s disease, the primary targets of the Medical Ghost’s environmental interventions, consistent, automated monitoring and adjustment become essential for reliable care.
Furthermore, certain health events, such as sleep apnea episodes, fundamentally require automated monitoring as the patient cannot engage while the event occurs.For the Ghost, high-fidelity automation may be a prerequisite for effective care consistency, especially when addressing subtle, pre-symptomatic physiological markers.
Algorithmic Paternalism and Subliminal Influence
The ghost’s operational model fundamentally embraces a high degree of technological paternalism.
The Shift to Ends Paternalism
Paternalism is ethically defined by the application of an externally defined notion of what is good for a person. In less aggressive forms, AI systems employ "nudges", subtle changes to the environment or workflow designed to guide human decisions, constituting means paternalism.The Medical Ghost, however, transcends mere guidance; it autonomously executes the desired therapeutic action (eg. changing light frequencies or playing specific tones).
This shift represents strong ends paternalism, where the AI system determines the optimal outcome and directly effects it without requiring any conscious choice or action from the individual. The ethical standard for such action must demonstrate extremely high certainty of safety and clinical benefit to justify overriding conscious autonomy.
Subliminal Therapeutic Efficacy
The mechanism by which the Ghost intervenes without awareness is not speculative; it leverages known pathways of subconscious influence. Research has demonstrated that individuals exposed to positive age stereotypes subliminally (flashing words like "spry" too quickly for conscious detection) exhibited improved physical function, such as balance, lasting for several weeks post-intervention.
Crucially, subliminal information is known to trigger the placebo effect (symptom improvement from inert cues) and its opposite, the nocebo effect (symptom worsening from negative cues). The Ghost capitalises on this psychological sensitivity, transforming the patient's home environment into a closed-loop therapeutic tool that modulates health through non-conscious stimuli.
Developing Protocols for Autonomous Care
The necessity of the Medical Ghost’s non-aware intervention mechanism, combined with the established legal rights to bodily autonomy, mandates the definition of a new ethical standard.
The ethical standard required for the Ghost cannot be satisfied by traditional "informed consent," which presumes conscious choice, nor by "emergency presumed consent." Instead, a unique Ambient Consent Protocol must be established. This protocol requires an initial, extremely detailed informed consent process covering the full range of potential non-conscious interventions, the specific environmental modalities used (light, sound, temperature), and the maximum permissible degree of environmental modification.
Crucially, this consent must be paired with an easily accessible, always-active mechanism for the immediate, unconditional withdrawal of consent or opt-out, despite the system’s best-interest mandate. If the system detects early depression through speech patterns and adjusts ambient colour temperature to influence mood, the patient must have proactively consented to this specific category of automated psychological intervention, recognising their right to revoke that consent at any time.
Furthermore, the power of non-conscious influence introduces a catastrophic risk: the Nocebo Ghost. Given that subliminal cues can trigger both beneficial placebo effects and harmful nocebo effects, any design flaw or data bias in the black-box algorithmic control of the environmental modulation could inadvertently introduce negative subconscious cues. This could result in subconscious harm, a degradation of the patient’s neurological or physical state, that the patient cannot consciously identify or report. Managing this necessitates ultra high validation standards and mandates for white-box components or extraordinary documentation to allow for forensic tracing of causality in the event of undetectable harm.
Regulatory Frontiers and Liability Architecture
The integration of medical-grade autonomy into consumer home infrastructure creates significant stress points across existing regulatory, data privacy, and liability frameworks, requiring novel legal architectures.
The Dual Regulatory Challenge: SaMD and Consumer IoT
High-Risk SaMD Classification and Oversight
Given its autonomous diagnostic and therapeutic function, the Medical Ghost falls into the category of a high-risk AI system, subjecting it to stringent compliance requirements, similar to those imposed by the European Union’s AI Act. Regulatory focus in the United States must address the risks associated with automation bias and clinical deskilling, mandating continuous monitoring and risk assessment of the AI system's dynamic effects. The autonomy of the device means that the risk of patient harm stems not only from traditional component failure but from algorithmic error and resulting clinical errors.
Navigating the Privacy Chasm
The Medical Ghost collects extensive Electronic Protected Health Information (ePHI) through continuous monitoring of physiological proxies like gait and heart rate. However, the core platform, the smart home system, is frequently operated by technology vendors who are not HIPAA-covered entities. This structural division creates a regulatory paradox. While traditional HIPAA regulations govern covered entities and their business associates, non-covered digital health vendors are increasingly being scrutinised and penalised by the Federal Trade Commission (FTC), which uses Section 5 of the FTC Act to target unfair or deceptive data practices, particularly concerning privacy policy misalignment.
Furthermore, the FTC is actively enforcing the HITECH Act’s Health Breach Notification Rule against non-HIPAA vendors of personal health records and connected devices. A system failure of the Medical Ghost is thus concurrently a medical device malfunction subject to FDA oversight and a consumer data breach subject to FTC and state privacy law enforcement, underscoring the fragmented jurisdiction over the technology.
Data Risk Vectors and Mental Privacy
The operation of the Medical Ghost introduces several critical data risk vectors. The unauthorised training of AI models on patient data without explicit authorisation or a defined treatment, payment, or healthcare operations justification constitutes a significant HIPAA violation risk. The automated nature of the data flow also amplifies risks related to documentation accuracy, potentially inserting PHI into the wrong chart or disclosing it improperly, leading to malpractice and privacy breaches. The opacity of smart home terms of service further exacerbates the "privacy paradox," where individuals express concern over privacy but provide data due to complex, lengthy documents that require specialised expertise to understand.
Beyond technical security, the system’s continuous ambient surveillance of movement, speech, and physiological patterns introduces the erosion of mental privacy. The pervasive sense of constant scrutiny can generate feelings of unease, stress, and discomfort, leading individuals to constantly second-guess their behaviors and effectively creating a "monitored self". Policymakers must move beyond simply securing data (HIPAA) to mitigating the psychological cost of surveillance. This necessitates mandatory design features such as robust data minimisation, strict purpose-limited use, and real-time user control over data sharing and collection to reduce feelings of surveillance anxiety.
Accountability Frameworks for Autonomous Harm
The advent of the autonomous intervention challenges traditional tort law, which is structured around human agency. A framework for assigning accountability must reconcile the high-risk nature of autonomous decision-making with the need to foster innovation.
Joint and Shared Liability
Accountability for autonomous AI decisions in healthcare must be treated as a shared dependency across multiple actors. Legal frameworks are required to establish clear guidelines for joint responsibility, ensuring that liability is distributed appropriately among AI developers, healthcare providers and the technology maintenance personnel. The AI device's specific degree of autonomy in a given incident must serve as the primary determinant for liability allocation.
Manufacturer and Provider Responsibility
In cases of autonomous AI, the creators must assume liability for harms that occur when the device is used properly and on-label, necessitating that manufacturers obtain comprehensive medical malpractice insurance covering algorithmic failure. This shift reflects trends seen in other autonomous industrial sectors, such as autonomous vehicles and machinery, where traditional insurance policies must be restructured to cover technology-driven risks, including software failures and cybersecurity breaches.
Conversely, the healthcare provider remains responsible for the proper clinical use and maintenance of the device, and maintains full legal liability for any non-autonomous (assistive) AI functions. Providers must also ensure the AI systems undergo rigorous testing and monitoring to minimise the risk of error and safeguard patient well-being.
The Challenge of Demonstrating Explainability (XAI)
The ability to assign fault hinges on algorithmic transparency, or Explainable AI (XAI). However, the most effective deep learning algorithms often function as "black box" models, making it extraordinarily difficult to determine the causal pathway by which the AI arrived at a given output, for instance, why it chose a specific light frequency for intervention. If a subtle environmental intervention causes unexpected or negative harm, tracing the causality back through ambient sensor data, complex neuro-algorithmic processes, and the environmental modulator presents an unparalleled forensic and legal challenge. Regulatory mandates must therefore impose requirements for "white-box" documentation or rigorous external auditing of all autonomous therapeutic decision-making pathways to ensure legal accountability can be met.
Proposed Multi-Tier Accountability Model for Autonomous Harms
Societal Impact and Strategies for Health Equity
The introduction of the Medical Ghost will profoundly affect the clinical workforce, the doctor-patient dynamic, and the existing structure of health equity.
Impact on the Human Element of Care
Mitigating Provider Burnout and Efficiency
Autonomous AI, such as ambient AI scribes, has demonstrated significant utility in alleviating administrative burdens, reducing documentation requirements, and improving operational efficiency for healthcare providers. Studies show notable improvements in interpersonal disengagement scores among providers, suggesting ambient AI can enhance professional fulfilment.
Erosion of "Connective Labour"
Despite gains in efficiency, reliance on AI systems for interaction and diagnosis risks eroding "connective labour", the essential human work of forging emotional understanding through empathetic listening and deep interactivity. If the Medical Ghost provides all initial diagnostic and monitoring insights, physicians may enter patient conversations already mediated by the algorithm’s summary, leading to a depersonalisation crisis in care. Furthermore, time saved by AI may not translate into longer, more effective patient communication but instead be used to increase patient volume, further deteriorating the emotional doctor-patient relationship.
Deskilling Risk
Widespread reliance on autonomous systems for core functions like physiological monitoring and pre-symptomatic diagnosis carries the substantial risk of clinical deskilling. Healthcare personnel may lose fundamental diagnostic and treatment planning expertise, increasing the vulnerability of the entire healthcare system should the AI fail or present misleading data.
Algorithmic Bias and Amplified Inequity
The effectiveness of the Medical Ghost depends entirely on the fidelity and representativeness of its training data. Flawed data design represents the single greatest threat to health equity.
Mechanisms of Bias in Ambient Systems
Algorithmic bias is defined as the application of an algorithm that compounds and amplifies existing societal inequities (socioeconomic status, race, gender) within health systems. Bias often results from unrepresentative training data; for example, AI models used for cardiovascular risk scoring have been shown to be less accurate for African American patients when trained predominantly on Caucasian data.
Similarly, algorithms trained primarily on male data sets are significantly less accurate when applied to female patients for predicting cardiac events or analysing chest X-rays. The lack of metadata (such as socioeconomic status or sexual orientation) in traditional health records prevents the assembly of truly representative datasets, making bias identification extremely difficult in "black box" deep learning models.
The Diagnostic Bias Amplification Loop
A critical consequence of this embedded bias is the creation of a Diagnostic Bias Amplification Loop. If the Medical Ghost’s passive monitoring layer, designed for early, subtle detection (e.g., detecting Parkinson's signs through gait changes), exhibits algorithmic bias, specific demographics will receive inaccurate automated care. Most critically, underrepresented groups may receive no intervention for real symptoms because the algorithm fails to recognise their physiological baseline as abnormal. This biased assessment is then transmitted to the human physician.
The physician, operating under time pressure and potentially exhibiting automation bias (over-reliance on the technology), may fail to manually screen the patient, thereby short-circuiting critical human judgment and embedding the initial algorithmic inequity into the clinical record and treatment path.
Socioeconomic Data Bias and Accessibility
Autonomous agents have the potential to democratise consistent, high-quality care, particularly by providing access to populations lacking specialist cardiology or neurology care. However, the initial high cost associated with smart home retrofitting, technology availability, and maintenance suggests that the Medical Ghost will initially be adopted primarily by higher socioeconomic, technically proficient demographics.
If foundational clinical trials and subsequent training datasets are derived predominantly from these early adopters, the resulting algorithms will inherently suffer from Socioeconomic Data Bias, ensuring structural failure to generalise safely to lower-income or medically vulnerable communities.
Policymakers must mandate that the development and deployment models actively incorporate strategies from interdisciplinary working groups, such as those focusing on AI equity, to address underrepresentation and ensure inclusive design.
Conclusion: Charting the Future of Automated Health
Recapitulation of the Paradox
The Medical Ghost represents a pivotal moment in medical history, promising personalised, proactive, and highly effective care delivered through continuous, autonomous environmental intervention. This model, however, establishes a fundamental paradox: maximum clinical optimisation appears achievable only at the expense of conscious patient autonomy, requiring a level of automated paternalism and continuous data surveillance previously considered ethically unacceptable.
The strategic challenge for policymakers and industry leaders is not whether to adopt this technology, but how to govern it responsibly so that the benefits of automation do not erode the foundational principles of medical ethics and equity.
Policy Imperatives for Responsible Automation
To ensure safe, ethical, and equitable deployment of C-LAMS systems, regulatory bodies must move swiftly from reactive policy to proactive governance, establishing three core imperatives:
Mandating Ambient Consent Protocols: Traditional informed consent is insufficient for non-conscious, autonomous therapeutic interventions. New frameworks must define an Ambient Consent Protocol that requires explicit, layered permission for the category and range of non-conscious interventions, alongside an easily accessible and always-active mechanism for unconditional opt-out or revocation of consent, thereby preserving the fundamental right to bodily autonomy.
Establishing a Unified Accountability Architecture: The fragmented legal landscape spanning SaMD (FDA/HIPAA) and Consumer IoT (FTC/State Law) must be bridged. A unified regulatory framework must mandate a Joint Accountability Model that places high liability on AI manufacturers for autonomous algorithmic errors and design flaws, while simultaneously requiring mandatory explainability (XAI) or rigorous documentation to allow for forensic causality tracing in cases of unexpected harm, particularly the nocebo effect.
Implementing Mandatory Equity Audits and Inclusive Data Strategies: To counteract the Diagnostic Bias Amplification Loop and Socioeconomic Data Bias, regulatory authorization must be conditional upon continuous, demonstrable equity audits. Developers must be required to prove algorithmic accuracy across diverse demographic and socioeconomic groups, and adopt aggressive strategies for collecting representative data from underrepresented populations to ensure the benefits of autonomous care democratise, rather than divide, access to high-quality medicine.
Final Outlook
The trajectory toward patient automation is now technologically inevitable. The Medical Ghost, operating invisibly within the confines of private life, has the potential to redefine health monitoring and preventative care. The critical task for regulatory bodies is to rapidly structure a robust governance system that mandates transparency, enforces accountability, and preserves human dignity and equity in an age defined by the invisible, autonomous doctor. Failure to establish these proactive guardrails will result in a healthcare system optimized for clinical output but compromised by fundamental ethical and legal fragility.
Nelson Advisors > MedTech and HealthTech M&A
Nelson Advisors specialise in mergers, acquisitions and partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
We share our views on the latest Healthcare Technology mergers, acquisitions and partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide#Divestitures #Corporate #Portfolio #Optimisation #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising#BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Us @ HealthTech events
Digital Health Rewired > 18-19th March 2025 > Birmingham, UK
NHS ConfedExpo > 11-12th June 2025 > Manchester, UK
HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands
Barclays Health Elevate > 25th June 2025, London, UK
HIMSS AI in Healthcare > 10-11th July 2025, New York, USA
Bits & Pretzels > 29th Sept-1st Oct 2025, Munich, Germany
World Health Summit 2025 > October 12-14th 2025, Berlin, Germany
HealthInvestor Healthcare Summit > October 16th 2025, London, UK
HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA
Web Summit 2025 > 10th-13th November 2025, Lisbon, Portugal
MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany
Venture Capital World Summit > 2nd December 2025, Toronto, Canada
